The Middle EAST Neoantigen Targeted Therapies Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.25 billion by 2034, registering a CAGR of 10.5%. This growth trajectory is primarily driven by the increasing prevalence of cancer cases in the region, alongside advancements in personalized medicine and immunotherapy. The region's healthcare infrastructure is evolving,...